09 April 2026
09 April 2026
The rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability.
This funding will boost the US’s antibiotic manufacturing capacity, while helping to curb the threat of antimicrobial resistance (AMR) across America.
The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress two of its bispecific ADC programmes to clinical development.
The fund’s resources allow it to invest up to €150m, helping businesses advance clinical development.
Everest Medicines will pay $250m in three instalments: $150m at closing, two $50m payments in 2028, 2029.
Pharma trade bodies have warned of negative impacts from tariffs, while analysts point to geopolitical catalysts.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
